This study is aimed to assess the hypothesis that instillation of fibrin glue with the induction of local conditions using Infliximab, may be useful in the treatment of perianal Crohn's disease.
Patients with perianal fistulae of Crohn's disease will be prospectively enrolled and receive 3 doses of Infliximab. If reduction of fistula associated discharge of at least 50% will be recorded, commercially available fibrin glue will be instilled into the fistula tract using standard surgical techniques. The patients will be followed for 6 months for fistula healing and complications.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Meir Medical Center
Kfar Saba, Israel
Tel Aviv Medical Center
Tel Aviv, Israel
Sheba Medical Center
Tel Litwinsky, Israel
Assaf Harofe Medical Center
Zrifin, Israel
Fistula healing
Quality of life
Complications
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.